SPATA22

Summary

SPATA22 (spermatogenesis associated 22, HGNC:30705) is a protein-coding gene on chromosome 17p13.2, encoding Spermatogenesis-associated protein 22 (Q8NHS9). Meiosis-specific protein required for homologous recombination in meiosis I.

Predicted to be involved in regulation of meiotic cell cycle. Predicted to act upstream of or within several processes, including fertilization; gamete generation; and meiosis I cell cycle process. Predicted to be located in chromosome.

Source: NCBI Gene 84690 — RefSeq curated summary.

At a glance

• Gene–disease (curated): infertility disorder (Moderate, GenCC) — +1 more curated relationship
• GWAS associations: 1
• Clinical variants (ClinVar): 195 total — 7 pathogenic, 6 likely-pathogenic
• Phenotypes (HPO): 14
• MANE Select transcript: NM_001170698

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30705
Approved symbol	SPATA22
Name	spermatogenesis associated 22
Location	17p13.2
Locus type	gene with protein product
Status	Approved
Aliases	NYD-SP20
Ensembl gene	ENSG00000141255
Ensembl biotype	protein_coding
OMIM	617673
Entrez	84690

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 14 protein_coding

ENST00000268981, ENST00000355380, ENST00000397168, ENST00000541913, ENST00000570318, ENST00000571553, ENST00000571607, ENST00000572582, ENST00000572969, ENST00000573128, ENST00000574051, ENST00000574457, ENST00000574797, ENST00000575375

RefSeq mRNA: 8 — MANE Select: NM_001170698 NM_001170695, NM_001170696, NM_001170697, NM_001170698, NM_001170699, NM_001321336, NM_001321337, NM_032598

CCDS: CCDS11027, CCDS54066, CCDS54067, CCDS82036

Canonical transcript exons

ENST00000572969 — 9 exons

Exon	Start	End
ENSE00002649723	3440019	3440338
ENSE00002668971	3471682	3471819
ENSE00003533661	3448807	3449149
ENSE00003577613	3462483	3462578
ENSE00003580316	3462707	3462767
ENSE00003628189	3443174	3443271
ENSE00003650134	3469283	3469398
ENSE00003653361	3446472	3446601
ENSE00003681574	3467426	3467554

Expression profiles

Bgee: expression breadth ubiquitous, 161 present calls, max score 98.96.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.4113 / max 223.2871, expressed in 76 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
163845	0.2556	6
163846	0.1527	71
208031	0.0030	2

Top tissues by expression

252 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	98.96	gold quality
right testis	UBERON:0004534	98.55	gold quality
left testis	UBERON:0004533	98.39	gold quality
testis	UBERON:0000473	95.98	gold quality
adult organism	UBERON:0007023	95.12	gold quality
secondary oocyte	CL:0000655	92.11	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	91.58	gold quality
oocyte	CL:0000023	89.63	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	88.59	gold quality
endothelial cell	CL:0000115	67.49	silver quality
sural nerve	UBERON:0015488	66.61	gold quality
pancreatic ductal cell	CL:0002079	64.46	silver quality
calcaneal tendon	UBERON:0003701	59.47	gold quality
gastrocnemius	UBERON:0001388	58.79	gold quality
muscle of leg	UBERON:0001383	58.70	gold quality
ganglionic eminence	UBERON:0004023	57.84	gold quality
prefrontal cortex	UBERON:0000451	57.75	gold quality
tibialis anterior	UBERON:0001385	57.38	silver quality
caudate nucleus	UBERON:0001873	56.31	gold quality
tibial nerve	UBERON:0001323	56.28	gold quality
hypothalamus	UBERON:0001898	56.04	gold quality
amygdala	UBERON:0001876	55.72	gold quality
putamen	UBERON:0001874	55.69	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	55.21	gold quality
hindlimb stylopod muscle	UBERON:0004252	55.18	gold quality
substantia nigra	UBERON:0002038	55.15	gold quality
nucleus accumbens	UBERON:0001882	55.00	gold quality
subcutaneous adipose tissue	UBERON:0002190	54.92	gold quality
ventricular zone	UBERON:0003053	54.74	gold quality
omental fat pad	UBERON:0010414	54.71	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-GEOD-134144	yes	1487.49
E-ANND-3	no	2.09

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

15 targeting SPATA22, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-4503	99.85	71.45	1869
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-548AZ-3P	99.82	70.56	3549
HSA-MIR-548BC	99.82	70.61	3524
HSA-MIR-548E-3P	99.82	70.59	3514
HSA-MIR-548F-3P	99.82	70.59	3540
HSA-MIR-548A-3P	99.76	70.58	3524
HSA-MIR-7159-5P	99.53	72.12	2472
HSA-MIR-4272	98.76	68.74	1810
HSA-MIR-4703-5P	98.53	70.13	1645
HSA-MIR-3942-5P	98.52	69.51	1517

Literature-anchored findings (GeneRIF, showing 5)

• Data indicate that the positive expression of studied genes fertilization rate for GAPDHS positive subset was 66%, ACR - 71%, SPATA22 - 68%, MND1 - 70%, pregnancy rates were 8%, 6%, 18% and 36% respectively. (PMID:23675907)
• The meiosis-specific MEIOB-SPATA22 complex cooperates with RPA to form a compacted mixed MEIOB/SPATA22/RPA/ssDNA complex. (PMID:33812231)
• Whole-exome sequencing of consanguineous families with infertile men and women identifies homologous mutations in SPATA22 and MEIOB. (PMID:34392356)
• Bi-allelic SPATA22 variants cause premature ovarian insufficiency and nonobstructive azoospermia due to meiotic arrest. (PMID:35285020)
• Nuclear localization of human MEIOB requires its NLS in the OB domain and interaction with SPATA22. (PMID:36331299)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	spata22	ENSDARG00000098537
mus_musculus	Spata22	ENSMUSG00000112920
rattus_norvegicus	Spata22	ENSRNOG00000037307

Protein

Protein identifiers

Spermatogenesis-associated protein 22 — Q8NHS9 (reviewed: Q8NHS9)

Alternative names: Testis development protein NYD-SP20

All UniProt accessions (9): A0A140VJV9, Q8NHS9, F5GWB9, I3L1L5, I3L2B9, I3L3S6, I3L4D7, I3L4R7, I3L517

UniProt curated annotations — full annotation on UniProt →

Function. Meiosis-specific protein required for homologous recombination in meiosis I.

Subunit / interactions. Component of a multiprotein complex with MEIOB and RPA2. Interacts with MEIOB. Interacts with the complex BRME1:HSF2BP:BRCA2.

Subcellular location. Chromosome.

Tissue specificity. Highly expressed in adult testis.

Disease relevance. Spermatogenic failure 96 (SPGF96) [MIM:621001] An autosomal recessive, male infertility disorder characterized by non-obstructive azoospermia due to spermatogenesis arrest at the zygotene stage. The disease is caused by variants affecting the gene represented in this entry. Premature ovarian failure 25 (POF25) [MIM:621002] A form of premature ovarian failure, an ovarian disorder defined as the cessation of ovarian function under the age of 40 years. It is characterized by oligomenorrhea or amenorrhea, in the presence of elevated levels of serum gonadotropins and low estradiol. POF25 inheritance is autosomal recessive. The disease is caused by variants affecting the gene represented in this entry.

Isoforms (3)

UniProt ID	Names	Canonical?
Q8NHS9-1	1, NYD-SP20C, NYD-SP20D	yes
Q8NHS9-2	2, NYD-SP20B
Q8NHS9-3	3

RefSeq proteins (8): NP_001164166, NP_001164167, NP_001164168, NP_001164169, NP_001164170, NP_001308265, NP_001308266, NP_115987 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR033536	Spata22	Family

UniProt features (19 total): sequence variant 6, compositionally biased region 4, region of interest 3, sequence conflict 3, splice variant 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NHS9-F1	61.02	0.30

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 88 (showing top): GOBP_MEIOTIC_CHROMOSOME_SEGREGATION, GOBP_CHROMOSOME_ORGANIZATION, GOBP_REGULATION_OF_MEIOTIC_CELL_CYCLE, GOBP_ORGANELLE_FISSION, GOBP_REPRODUCTIVE_SYSTEM_DEVELOPMENT, GOBP_REGULATION_OF_CELL_CYCLE, GOBP_REGULATION_OF_REPRODUCTIVE_PROCESS, GOBP_DNA_DAMAGE_RESPONSE, GOBP_CHROMOSOME_ORGANIZATION_INVOLVED_IN_MEIOTIC_CELL_CYCLE, GOBP_DNA_BIOSYNTHETIC_PROCESS, GOBP_DNA_SYNTHESIS_INVOLVED_IN_DNA_REPAIR, GOBP_HOMOLOGOUS_CHROMOSOME_SEGREGATION, GOBP_MEIOTIC_CELL_CYCLE_PROCESS, WEBER_METHYLATED_HCP_IN_SPERM_UP, GOBP_FERTILIZATION

GO Biological Process (8): meiotic DNA repair synthesis (GO:0000711), homologous chromosome pairing at meiosis (GO:0007129), fertilization (GO:0009566), spermatocyte division (GO:0048137), regulation of meiotic cell cycle (GO:0051445), reproductive system development (GO:0061458), gamete generation (GO:0007276), meiotic cell cycle (GO:0051321)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (1): chromosome (GO:0005694)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
sexual reproduction	3
reproductive process	2
DNA synthesis involved in DNA repair	1
meiosis I cell cycle process	1
homologous chromosome segregation	1
chromosome organization involved in meiotic cell cycle	1
spermatogenesis	1
cell division	1
meiotic cell cycle	1
regulation of cell cycle	1
regulation of reproductive process	1
system development	1
multicellular organismal reproductive process	1
cell cycle	1
meiotic nuclear division	1
binding	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

812 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SPATA22	MEIOB	Q8N635	968
SPATA22	HSF2BP	O75031	775
SPATA22	SYCP3	Q8IZU3	632
SPATA22	BRME1	Q0VDD7	620
SPATA22	SYCE3	A1L190	617
SPATA22	SYCE2	Q6PIF2	597
SPATA22	HORMAD1	Q86X24	597
SPATA22	SPO11	Q9Y5K1	581
SPATA22	SYCP1	Q15431	541
SPATA22	SYCE1	Q8N0S2	538
SPATA22	HORMAD2	Q8N7B1	537
SPATA22	HFM1	A2PYH4	523
SPATA22	SPATA17	Q96L03	518
SPATA22	SHPK	Q9UHJ6	506
SPATA22	SPATA4	Q8NEY3	496
SPATA22	PRDM9	Q9NQV7	496

IntAct

84 interactions, top by confidence:

A	B	Type	Score
SPATA22	GOLGA2	psi-mi:“MI:0915”(physical association)	0.560
GOLGA2	SPATA22	psi-mi:“MI:0915”(physical association)	0.560
HSF2BP	SPATA22	psi-mi:“MI:0915”(physical association)	0.560
SPATA22	DR1	psi-mi:“MI:0915”(physical association)	0.560
SPATA22		psi-mi:“MI:0915”(physical association)	0.560
SPATA22	GFAP	psi-mi:“MI:0915”(physical association)	0.560
GTF2B	SPATA22	psi-mi:“MI:0915”(physical association)	0.560
SPATA22	NDUFV2	psi-mi:“MI:0915”(physical association)	0.560
SPATA22	NF2	psi-mi:“MI:0915”(physical association)	0.560
SPATA22	PMP22	psi-mi:“MI:0915”(physical association)	0.560
SPATA22	GTF3C3	psi-mi:“MI:0915”(physical association)	0.560
SPATA22	DNAJB6	psi-mi:“MI:0915”(physical association)	0.560
SPTLC1	SPATA22	psi-mi:“MI:0915”(physical association)	0.560
SPATA22	ATXN10	psi-mi:“MI:0915”(physical association)	0.560
SPATA22	JPH3	psi-mi:“MI:0915”(physical association)	0.560
SOD1	SPATA22	psi-mi:“MI:0915”(physical association)	0.560
FUS	SPATA22	psi-mi:“MI:0915”(physical association)	0.560
SNCA	SPATA22	psi-mi:“MI:0915”(physical association)	0.560
HTT	SPATA22	psi-mi:“MI:0915”(physical association)	0.560
TARDBP	SPATA22	psi-mi:“MI:0915”(physical association)	0.560
LRRK2	SPATA22	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (16): SPATA22 (Two-hybrid), DES (Affinity Capture-MS), ACTA2 (Affinity Capture-MS), ACTBL2 (Affinity Capture-MS), SPATA22 (Two-hybrid), SPATA22 (Synthetic Lethality), HSF2BP (Two-hybrid), BLK (Affinity Capture-MS), ACTBL2 (Affinity Capture-MS), DES (Affinity Capture-MS), ACTA2 (Affinity Capture-MS), SPATA22 (Two-hybrid), SPATA22 (Affinity Capture-MS), SPATA22 (Two-hybrid), KDM1A (Two-hybrid)

ESM2 similar proteins: A2RVA7, A4IF98, F6UH96, O08901, O60566, O75113, P14629, P62283, P62285, P62286, P62287, P62289, P62290, P62291, P62292, P62293, P62294, P62297, Q08DB0, Q0P4I1, Q0VA42, Q17RS7, Q2TA20, Q32NQ8, Q4R7I0, Q5F3D1, Q5I2W8, Q5R789, Q5T5J6, Q5ZHV8, Q6A037, Q6DDH2, Q6DJS0, Q6NZY4, Q6XV80, Q7Y1C4, Q7Y1C5, Q7ZVM9, Q7ZXG4, Q7ZXT3

Diamond homologs: Q2TA20, Q5SV06, Q8NHS9, Q95JQ1

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

195 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	7
Likely pathogenic	6
Uncertain significance	95
Likely benign	32
Benign	45

Top pathogenic / likely-pathogenic (13)

Variant ID	HGVS	Classification
1420788	NM_000049.4(ASPA):c.34C>T (p.Gln12Ter)	Pathogenic
188940	NM_000049.4(ASPA):c.541C>A (p.Pro181Thr)	Pathogenic
2691735	NM_001170698.2(SPATA22):c.253del (p.Ser85fs)	Pathogenic
2736390	NM_000049.4(ASPA):c.209A>G (p.Asn70Ser)	Pathogenic
3370406	NM_001170698.2(SPATA22):c.400C>T (p.Arg134Ter)	Pathogenic
3370407	NM_001170698.2(SPATA22):c.31C>T (p.Arg11Ter)	Pathogenic
3370408	NM_001170698.2(SPATA22):c.900+1G>A	Pathogenic
1724393	NM_000049.4(ASPA):c.406_407del (p.Leu136fs)	Likely pathogenic
371178	NM_000049.4(ASPA):c.745-2A>G	Likely pathogenic
371463	NM_000049.4(ASPA):c.237-1G>T	Likely pathogenic
523964	NM_000049.4(ASPA):c.689_698del (p.Asp230fs)	Likely pathogenic
556181	NM_000049.4(ASPA):c.89T>C (p.Leu30Pro)	Likely pathogenic
556864	NM_000049.4(ASPA):c.796dup (p.Asp266fs)	Likely pathogenic

SpliceAI

2643 predictions. Top by Δscore:

Variant	Effect	Δscore
17:3446605:T:C	acceptor_gain	1.0000
17:3469277:CAATA:C	donor_loss	1.0000
17:3469278:AATAC:A	donor_loss	1.0000
17:3469279:ATACC:A	donor_loss	1.0000
17:3469280:TA:T	donor_loss	1.0000
17:3469281:A:AG	donor_loss	1.0000
17:3469282:C:A	donor_loss	1.0000
17:3469282:CCTG:C	donor_gain	1.0000
17:3469396:GACC:G	acceptor_loss	1.0000
17:3469397:ACC:A	acceptor_loss	1.0000
17:3469399:C:CG	acceptor_loss	1.0000
17:3474172:AAGG:A	donor_loss	1.0000
17:3474174:GGTA:G	donor_loss	1.0000
17:3474175:GTA:G	donor_loss	1.0000
17:3475834:ATT:A	donor_gain	1.0000
17:3481762:G:GT	donor_gain	1.0000
17:3489341:AGG:A	donor_loss	1.0000
17:3489343:G:A	donor_loss	1.0000
17:3489344:TAA:T	donor_loss	1.0000
17:3446601:CCTTT:C	acceptor_gain	0.9900
17:3446605:T:TC	acceptor_gain	0.9900
17:3449150:C:CC	acceptor_gain	0.9900
17:3467422:TTA:T	donor_loss	0.9900
17:3467423:TACCT:T	donor_loss	0.9900
17:3467424:ACC:A	donor_loss	0.9900
17:3467425:CCT:C	donor_loss	0.9900
17:3467551:CAGC:C	acceptor_gain	0.9900
17:3467553:GCC:G	acceptor_loss	0.9900
17:3467556:T:C	acceptor_loss	0.9900
17:3468830:G:C	donor_gain	0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000039541 (17:3475277 A>G), RS1000059047 (17:3453031 G>A,C), RS1000067615 (17:3468943 G>A), RS1000099953 (17:3469192 T>C), RS1000226849 (17:3444868 A>T), RS1000235126 (17:3510976 T>A), RS1000254278 (17:3493803 A>T), RS1000320439 (17:3460478 T>A), RS1000360851 (17:3513127 A>C), RS1000364486 (17:3501767 A>G), RS1000412151 (17:3474852 T>C), RS1000420815 (17:3451712 G>A), RS1000453602 (17:3452320 G>A), RS1000470293 (17:3465585 G>A), RS1000478747 (17:3499296 G>A)

Disease associations

OMIM: gene MIM:617673 | disease phenotypes: MIM:271900, MIM:616400, MIM:621001, MIM:621002

GenCC curated gene-disease

Disease	Classification	Inheritance
infertility disorder	Moderate	Autosomal recessive
genetic infertility	Moderate	Autosomal recessive

Mondo (6): Canavan disease (MONDO:0010079), isolated focal non-epidermolytic palmoplantar keratoderma (MONDO:0014622), spermatogenic failure 96 (MONDO:0975842), premature ovarian failure 25 (MONDO:0975843), infertility disorder (MONDO:0005047), (MONDO:0017143)

Orphanet (2): Canavan disease (Orphanet:141), Isolated focal non-epidermolytic palmoplantar keratoderma (Orphanet:448264)

HPO phenotypes

14 total (14 of 14 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000028	Cryptorchidism
HP:0000858	Irregular menstruation
HP:0002960	Autoimmunity
HP:0003251	Male infertility
HP:0008209	Premature ovarian insufficiency
HP:0008222	Female infertility
HP:0008232	Elevated circulating follicle stimulating hormone level
HP:0011462	Young adult onset
HP:0011961	Non-obstructive azoospermia
HP:0030087	Abnormal circulating testosterone concentration
HP:0030338	Abnormal circulating gonadotropin concentration
HP:0031039	Spermatocyte maturation arrest
HP:0031103	Decreased circulating antimullerian hormone circulation

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST009178_11	Caudal middle frontal gyrus volume	6.000000e-06

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D017825	Canavan Disease	C10.228.140.163.100.362.375; C10.228.140.695.625.375; C10.314.400.375; C10.574.500.300; C16.320.400.150; C16.320.565.189.362.375; C18.452.132.100.362.375; C18.452.648.189.362.375
D007246	Infertility	C12.100.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

5 total (human), top 5 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression, increases methylation	5
trichostatin A	increases expression	1
Vorinostat	increases expression	1
Benzo(a)pyrene	increases methylation	1
Aflatoxin B1	decreases methylation	1

Clinical trials (associated diseases)

114 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01388907	PHASE4	COMPLETED	Efficacity Assessment of PREVADH® in Adhesion Prevention in Gynaecologic Surgery
NCT01430650	PHASE4	COMPLETED	Endometrial Priming for Embryo Transfer
NCT02607319	PHASE4	COMPLETED	Low Molecular Weight Heparin to Improve Pregnancy Outcome in Patients With Recurrent Implantation Failure
NCT03169166	PHASE4	COMPLETED	The Use of GnRH Agonist Trigger for Final Follicle Maturation in Women Undergoing Assisted Reproductive Technologies
NCT03177122	PHASE4	UNKNOWN	Myo-Inositol- Based Co-treatment in Women With PCOS Undergoing Assisted Reproductive Technology
NCT03477929	PHASE4	UNKNOWN	Cetrorelix and Ganirelix Flexible Protocol for (IVF)
NCT03619707	PHASE4	COMPLETED	Oral Versus Vaginal Progesterone in the Luteal Support in Cryo-warmed Embryo Transfer Cycles
NCT03846544	PHASE4	COMPLETED	Double Pick up in Poor Prognosis Women
NCT05725512	PHASE4	RECRUITING	Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages
NCT06195163	PHASE4	NOT_YET_RECRUITING	TRAP Study: Testosterone for Androgen Receptor Polymorphism
NCT06763926	PHASE4	NOT_YET_RECRUITING	Intranasal Nafarelin For Triggering Oocyte Maturation
NCT00749853	PHASE3	SUSPENDED	Efficacy of Ovarian Stimulation Based on FSHR Genotype Status
NCT03238092	PHASE3	UNKNOWN	Comparison Between Testosterone and Estradiol Over the Homogenization of Follicular Cohort
NCT03803228	PHASE3	COMPLETED	Dual Ovarian Stimulation (DUOSTIM) for Poor Ovarian Responders
NCT04701034	PHASE2	COMPLETED	Intravenous Immunoglobulin and Prednisolone for RPL After ART.
NCT04850261	PHASE2	WITHDRAWN	Injection Free IVF
NCT06997900	PHASE2	RECRUITING	Menopur And Rekovelle Combination Study Version 2.0
NCT00657748	PHASE2	WITHDRAWN	Lithium and Acetate for Canavan Disease
NCT01330771	Not specified	COMPLETED	Assessment of the Therapeutic Utility of r-FSH in Association With hMG-HP
NCT01330784	Not specified	COMPLETED	Assessment of the Therapeutic Utility of hMG-HP
NCT01331720	Not specified	COMPLETED	Assessment of the Effectiveness and Tolerability of Ovarian Hyperstimulation
NCT01331733	Not specified	COMPLETED	Comparative Assessment of the Clinical Utility of Ovarian Stimulation With Menotropin Versus Menotropin Plus GnRH Antagonist
NCT01406964	Not specified	COMPLETED	Chlamidia Antibodies Test for Tubal Factor Screening
NCT01533350	Not specified	COMPLETED	Receptivity Assessment of Homogeneous Endometrium in Late Follicle Phase
NCT01955356	Not specified	COMPLETED	Embryo Implantation After Induced Endometrial Injury
NCT02081924	Not specified	RECRUITING	Reproductive Hormones During Sustained Administration of Kisspeptin
NCT02648555	Not specified	UNKNOWN	A Lifestyle Intervention to Improve in Vitro Fertilization Results
NCT03007043	Not specified	COMPLETED	Genetic Variation in Gonadotropin and Gonadotropin Receptor Genes and Suboptimal Response
NCT03023774	Not specified	COMPLETED	Use of Gcsf in Patients With Recurrent Ivf/Icsi Failure
NCT03065114	Not specified	COMPLETED	Retrospective Study on Clinical Results of Preimplantation Genetic Screening at Different Embryo Stage
NCT03085212	Not specified	ACTIVE_NOT_RECRUITING	Strategies for Pregnancy Achievement
NCT03085433	Not specified	COMPLETED	Sperm Selection by Microfluidic Separation Improves Embryo Quality
NCT03118219	Not specified	COMPLETED	Positive Adjustment Coping Intervention
NCT03156374	Not specified	COMPLETED	Timing Frozen Embryo Transfer by Following Two Different Methods
NCT03161873	Not specified	COMPLETED	Cycle and Pregnancy Monitoring With Wearable Sensor Technology (AVA)
NCT03173404	Not specified	COMPLETED	Benefits of Hysteroscopy Prior to Performing a Cycle of in Vitro Fertilization/Intracytoplasmic Sperm Injection
NCT03180827	Not specified	ACTIVE_NOT_RECRUITING	Female Fertility Preservation Using Ovarian Tissue Cryopreservation Before Highly Gonadotoxic Cancer Treatment
NCT03180918	Not specified	RECRUITING	Male Fertility Preservation Using Cryopreservation of Testicular Tissue Before Highly Gonadotoxic Cancer Treatment
NCT03250195	Not specified	TERMINATED	Non-invasive Detection of Male Infertility With FDG-PET/MRI (Spectroscopy and DWI)
NCT03269916	Not specified	UNKNOWN	Fertility and Ovarian Reserve Function in the Patient With Inflammatory Bowel Disease